PharmTech Drug Digest 11.20
News|Articles|November 19, 2015

Thermo Fisher Scientific Opens New Singapore Location

On Nov. 18, 2015 Thermo Fisher Scientific Inc., a life sciences research company, announced the opening of their new GMP clinical services facility in Singapore. This new facility is meant to help meet the growing demand for clinical supply services in the region.

According to a press release from the company, Thermo Fisher Scientific Inc. opened its first clinical services facility in Singapore in 2001. The new facility will be located on Toh Guan Road, Jurong East and is nearly 70,000 ft2-60% larger than the previous site. The new site will provide pharmaceutical and biotech companies with clinical supplies including GMP storage, local labeling, secondary packaging, comparator sourcing, handling, and distribution of ambient and cold chain supplies.

Leon Wyszkowski, Thermo Fisher’s vice-president of Clinical Services for North America and facility network, says Singapore is the company’s fastest growing market and contributor to their growth. According to the company, clinical trial studies conducted in emerging Asian markets have increased in the past ten years, as a result of lower study costs and large patient populations. 

Source: Thermo Fisher Scientific 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.